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Enadequate Masking
f Testosterone
he recent paper by Caminiti et al. (1) and the accompanying
ditorial (2) overlook an important caveat for interpreting the study
f testosterone effects in cardiac failure. Consistent with previous
tudies (3,4), they report a striking dichotomy between the failure
f testosterone to improve objective cardiac function with the
mprovement in peripheral noncardiac effects, most being effort
ependent. This disparity may involve the psychotropic effects of
estosterone involving either expectation, mood-elevating effects,
r both. Greater motivation and exertion for either reason would
ppear as improved effort-dependent muscular function and met-
bolic end points. Testosterone has mood-elevating effects that
nce led to its being patented as an antidepressant (5), and it
roduces hypomania at pharmacological doses in some men (6). In
ddition, testosterone administration invokes major expectation
ffects (7). In the latter context, testosterone administered by deep
ntramuscular gluteal injection of a large volume (4 ml) of oil-based
estosterone is readily distinguished from a saline injection of
nstated volume as placebo. This failure of proper masking in the
resent (1) and a previous study (3) opens the possibility that the
isparity between the improved subjective effort-dependent mea-
ures without change in objective cardiac function may reflect
sychological effects arising from improved mood and/or expecta-
ions. Although obtaining matching sterile oil vehicle placebo for
arenteral injection is difficult, effective masking of testosterone
ay require other modalities for which matching placebos are
ore readily available (e.g., gel) and should be a priority for future
tudies of testosterone effects.
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eply
e read with interest the letter by Dr. Handelsman and the issues
hat he raised on our study, but we cannot concur with him. As far
s the influence of testosterone supplementation on mood might
ave had on the improvement of muscular performance that we
bserved (1), it should be noted that the effect on mood occurs
sually at supraphysiological doses, whereas, in our study, patients
eceiving testosterone had testosterone levels within the normal
ange. This concept is supported by the study of Malkin et al. (2)
n which the improvement in functional capacity in congestive
eart failure patients receiving testosterone supplementation at
hysiological doses was not accompanied by any effect on mood
core. Regarding the different feeling of the deep muscular injec-
ion between the oil-based testosterone and placebo, because our
tudy did not have a crossover design, we believe that it is
xtremely difficult to hypothesize that patients receiving injections
f a new drug may distinguish between the oil-based testosterone
nd placebo. Finally, Dr. Handelsman suggests the use of gel-
ased testosterone for a better blinding of patients. We will
onsider this suggestion for future studies.
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eply
r. Handelsman raises concerns with regard to the interpretation
f findings in the recently published study by Caminiti et al. (1)
nd our accompanying editorial (2). His major point is related to
estosterone’s failure to improve cardiac function while having
eneficial peripheral effects—a dichotomy he suggests may be
xplained by the mood-elevating effects of testosterone. He also
aises concerns with regard to the suboptimal use of saline as
lacebo.
We have no problems with agreeing with Dr. Handelsman’s
iew, and these aspects should be taken into account in the
nterpretation of the effects of testosterone in heart failure. In fact,
he interaction between hormones such as testosterone, neuro-
ransmitters, and inflammatory markers such as cytokines is an
ttractive target for therapy in several disorders such as chronic
eart failure. Thus, if this mechanism contributes to the results of
he study by Caminiti et al. (1), it should encourage rather than
dvise against further studies in this field. Moreover, although the
uthors did not find any effect on myocardial function, further
ong-term studies are needed before making any firm conclusions.
here is clearly a need for new treatment modalities in heart
ailure, and testosterone supplementation might be an interesting
pproach, most probably operating through several mechanisms
ncluding those suggested by Dr. Handelsman.
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2009;54:928–9. pilated Cardiomyopathy
omplicates Pregnancy Outcome:
ut How?
n a recent issue of the Journal, Grewal et al. (1) showed that the
isk of adverse maternal events in pregnant women with dilated
ardiomyopathy (DCM) is considerable, but the underlying mech-
nisms (in addition to increased hemodynamic load) remain
ncertain. Medication was discontinued in many of the women
efore pregnancy or during the first trimester. Even without the
hysical burden of pregnancy, withdrawal of heart failure medica-
ion per se may lead to dramatic hemodynamic deterioration. It
hus would be interesting to know whether the pregnant women
hose medication was discontinued fared worse than those who
ontinued to take their normal medication. It should be noted that
everal beta-blockers, notably labetalol, can be used safely during
regnancy. Thus, pregnancy outcome may not be quite as dismal as
eported by Grewal et al. (1) when adequate therapy is provided.
Four of the 9 cases of heart failure occurred after delivery (1).
xidative stress rises during normal pregnancy, culminating in the
ast trimester. Several signaling pathways have been shown to be
ecessary for protecting the maternal heart, including STAT3. In
mouse model, a deletion of STAT3 caused proteolytic cleavage of
rolactin into a potent antiangiogenic, proapoptotic, and proin-
ammatory factor associated with the development of peripartum
ardiomyopathy (2). It is conceivable that peripartum oxidative
tress caused additional damage to the left ventricle. In this respect,
he fact that 5 women had doxorubicin-induced DCM may be
elevant, because oxidative stress is deemed to play an important
ole in this type of DCM. It thus would be interesting to know
hether Grewal et al. (1) found a difference in pregnancy outcome
etween the women with doxorubicin-induced DCM versus idio-
athic DCM.
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eply
e thank Dr. van den Berg and colleagues for their interest in our
aper (1), and agree that in addition to the increased hemodynamic
